CN Patent

CN111356460A — 用于治疗进展型形式的多发性硬化症的克拉屈滨疗法

Assigned to Merck Patent GmbH · Expires 2020-06-30 · 6y expired

What this patent protects

本发明涉及包含克拉屈滨的特定口服剂量、特定口服剂型和/或特定口服给药法的用途，其用于治疗进展型形式的多发性硬化症，尤其是原发性进展型多发性硬化症和/或继发性进展型多发性硬化症，以及基于其的治疗方法。

USPTO Abstract

本发明涉及包含克拉屈滨的特定口服剂量、特定口服剂型和/或特定口服给药法的用途，其用于治疗进展型形式的多发性硬化症，尤其是原发性进展型多发性硬化症和/或继发性进展型多发性硬化症，以及基于其的治疗方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN111356460A
Jurisdiction
CN
Classification
—
Expires
2020-06-30
Drug substance claim
No
Drug product claim
No
Assignee
Merck Patent GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.